A mesothelioma articles recently published in the scientific journal Lung Cancer that examined the benefits and costs Cisplatin and Pemetrexed in combination with Carboplatin and Pemetrexed for mesothelioma chemotherapy.
Cisplatin and pemetrexed combination chemotherapy is one of several options that chemotherapy has proven quite successful for treating patients with malignant pleural mesothelioma / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no treatment and treatment for malignant mesothelioma cancer without the unwanted side effects.
In the journal the researchers noted that "there are two phases of a randomized study in phase III shows the benefits for mesothelioma prognosis with the use of antifolates such as raltitrexed or pemetrexed, when combined with cisplatin. Research has shown the absolute increase in overall survival an average of 2.6 and 2.8 months, compared with single treatment for cisplatin. This makes a lot of institutions using Cisplatin and Pemetrexed as standard palliative chemotherapy treatment for malignant pleural mesothelioma.
"Unfortunately, the combination of Cisplatin and Pemetrexed produce undesirable toxic effects, and this led researchers to study other chemotherapy drugs to be combined with pemetrexed. The researchers said, "Recently, two phase II trials have evaluated the efficacy of Carboplatin and pemetrexed in MPM. Both studies showed overall response rate of 18.6 and 25%, with survival rates on average 12.7 and 14 months. As a continuation of these results, we have conducted a retrospective analysis of MPM patients treated with Carboplatin and Pemetrexed in our institution. "
In an effort to find a combination chemotherapy of mesothelioma with minimal toxicity and side effects, the researchers investigated further by replacing cisplatin with Carboplatin when paired with Pemetrexed. By using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma who were given a combination of Carboplatin and Pemetrexed and compare the results with the data of cisplatin combination chemotherapy with Pemetrexed.
Disease control rate (which is known in the absence of progressive signs of mesothelioma by CT scan) for the patients was 69 percent, and the percentage of partial response and stable disease by 28 percent and 41 percent. Clinical improvement is shown in figure 69 percent, the majority of patients reported an increase in profits after two cycles of chemotherapy. Toxicity is generally low and better than the toxicity of cisplatin with pemetrexed.
The average time to treatment failure was 4.6 months. The average overall survival in this study is 14 months, compared with cisplatin-pemetrexed for 12.1 months. The authors suggested, "In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, especially in patients who experience problems with the use of cisplatin."...